State Street’s PharmaCyte Biotech PMCB Stock Holding History

State Street’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-62,600	Closed	-$182K	–	4716
2023 Q1	$182K	Hold	62,600	–	–	﹤0.01%	4109
2022 Q4	$183K	Hold	62,600	–	–	﹤0.01%	4139
2022 Q3	$150K	Hold	62,600	–	–	﹤0.01%	4261
2022 Q2	$141K	Buy	62,600 +25,000	+66%	+$54.6K	﹤0.01%	4360
2022 Q1	$86K	Buy	+37,600	New	+$83.5K	﹤0.01%	4686

Other funds holding PMCB

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street's PMCB Position: Q2 2023 in Review

State Street sold out of PharmaCyte Biotech (PMCB) in Q2 2023, closing a stake of 62,600 shares — an estimated $182K sold.

State Street first reported a position in PMCB in Q1 2022 and held it in 5 quarters. The position peaked at $183K in Q4 2022. 29 funds tracked by Wall St. Rank hold PMCB as of Q2 2023.

State Street reported no remaining PharmaCyte Biotech position as of Q2 2023 after selling out during the quarter.
State Street sold 62,600 PharmaCyte Biotech shares in Q2 2023, an estimated $182K.
State Street first reported a position in PharmaCyte Biotech in Q1 2022 and held it in 5 quarters.
State Street's PharmaCyte Biotech position peaked at $183K in Q4 2022.
29 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.